Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartwatch and app boost CPAP use in heart patients?

NCT ID NCT05960175

Disease control Sponsor: Asten Sante Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether involving patients in managing CPAP machine alerts—using a connected watch and app—can improve how often they use the device. It includes 556 adults with sleep apnea who are at risk for heart problems and likely to struggle with CPAP adherence. The goal is to see if this approach leads to better treatment use and health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Connected watch and mobile app for CPAP telemonitoring
What this could lead to
If successful, this approach could help people with sleep apnea use their CPAP machine more consistently, improving heart health and quality of life.
What could go wrong
This is a relatively small, early-stage study focused on adherence, not a cure. Results may not apply to all patients, and the technology may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 556 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult with newly diagnosed OSA (with central apnea index \<5 ev/h), justifying CPAP and with low sleepiness (Epworth score \<11 at inclusion). * Patient with at least 1 cardiovascular risk factor (obesity, type I or II diabetes with or without treatment, permanent hypertension with or without treatment, heart failure with preserved ejection fraction, valve disease, history of atrial fibrillation, history of ischaemic heart disease, history of stroke). * Patient with a smartphone and who agrees to use connected objects during the study. * Signed informed consent form, * Subject affiliated to a health insurance system, or is a beneficiary. Exclusion Criteria: * Patients already fitted with a CPAP machine, * Patients with permanent atrial fibrillation, * Patients whose state of health is not stable or requires heavy treatment, * Patients with cognitive problems. * Patients participating in another intervention research in pulmonology. * Vulnerable subject

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cheyne-Stokes Respiration obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSA

Contacts and locations

Locations

  • AP-HP Bichat Claude Bernard

    Paris, 75018, France

  • AP-HP Hôpital Européen Georges

    Paris, France, 75015, France

  • AP-HP Pitié Salpêtrière

    Paris, 75013, France

  • CH Départemental Vendée

    La Roche-sur-Yon, France, 85925, France

  • CH Le Mans

    Le Mans, 72037, France

  • CH Versailles

    Le Chesnay, 78150, France

  • CHU Angers - Service de pneumologie

    Angers, 49100, France

  • CHU Dijon-Bourgogne

    Dijon, 21000, France

  • CHU Nancy

    Nancy, 54511, France

  • CHU Rouen - Charles Nicolle

    Rouen, 76000, France

  • Polyclinique Saint-Laurent - Groupe médical de pneumologie

    Rennes, 35000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.